What is Xenocor?
Founded in 2016, Xenocor specializes in the development of disposable, fog-free laparoscope technologies. The company addresses a persistent challenge in the operating room: the obstruction of visual fields during complex procedures. By providing a sterile, single-use solution, Xenocor eliminates the need for traditional anti-fogging measures, thereby reducing procedural time and enhancing patient safety. Its market position is defined by a commitment to high-volume surgical environments where reliability and clarity are paramount for successful clinical outcomes.
How much funding has Xenocor raised?
Xenocor has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2023): $10M with participation from Patel Family Investments, GenHenn Venture Fund I, Barvest Ventures, and Baranco Investments
Key Investors in Xenocor
Patel Family Investments
A private investment firm focused on long-term capital appreciation and supporting disruptive technologies in the healthcare sector.
GenHenn Venture Fund I
An early-stage venture fund specializing in medical device innovation and life sciences infrastructure.
Barvest Ventures
A strategic investment group that provides growth capital to companies transforming clinical workflows and surgical standards.
What's next for Xenocor?
With this major enterprise-level funding, Xenocor is poised to accelerate its commercial expansion and deepen its research and development pipeline. The strategic allocation of this capital will likely focus on scaling manufacturing capabilities to meet rising demand for disposable surgical tools and expanding its footprint within major hospital networks. As the healthcare industry shifts toward value-based care and improved surgical throughput, Xenocor's technology offers a scalable solution that aligns with the broader trend of optimizing operating room efficiency through advanced, single-use medical devices.
See full Xenocor company page
